NA Fluorescent in Situ Hybridization (FISH) Market - Industry Trends and Forecast to 2030

Description

List of Tables

The North America Fluorescent in Situ Hybridization (FISH) market is projected to register a CAGR of 8.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

North America Fluorescent in Situ Hybridization (FISH) Market, By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the North America Fluorescent in Situ Hybridization (FISH) market are:

Growing demand for better quality healthcare for genetic disorders and the rising adoption of personalized medicine

Increasing use of the FISH technique due to the rise in patients with breast cancer and other chronic diseases

Market Players

Some of the major market players operating in the North America Fluorescent in Situ Hybridization (FISH) market are:

Thermo Fisher Scientific Inc.

Bio-Techne

Abbott

Agilent Technologies, Inc.

Merck KGaA

F. Hoffmann-La Roche Ltd

Abnova Corporation

BioDot

Biocare Medical, LLC

Abcam plc.

Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation)

BIOZOL Diagnostics Vertrieb GmbH

Zytomed Systems GmbH

Genemed Biotechnologies, Inc.

1 INTRODUCTION 67

1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW 67
1.4 CURRENCY AND PRICING 69
1.5 LIMITATIONS 69
1.6 MARKETS COVERED 70

2 MARKET SEGMENTATION 73

2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 MARKET APPLICATION COVERAGE GRID 81
2.8 PRODUCT LIFELINE CURVE 82
2.9 DBMR MARKET POSITION GRID 83
2.10 VENDOR SHARE ANALYSIS 85
2.11 SECONDARY SOURCES 86
2.12 ASSUMPTIONS 86

3 EXECUTIVE SUMMARY 87

4 PREMIUM INSIGHTS 90

4.1 PORTER'S FIVE FORCES 91
4.2 PESTEL ANALYSIS 92
4.3 INDUSTRY INSIGHTS 93
4.4 CONCLUSION 94

5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 95

6 MARKET OVERVIEW 97

6.1 DRIVERS 99
- 6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 99
- 6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 99
- 6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 100
- 6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 100
6.2 RESTRAINTS 101
- 6.2.1 HIGH COST OF FISH TESTING 101
- 6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 101
6.3 OPPORTUNITIES 102
- 6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 102
- 6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 102
6.4 CHALLENGES 103
- 6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 103
- 6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 103

7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 104

7.1 OVERVIEW 105
7.2 CONSUMABLES 108
- 7.2.1 FISH PROBE 108
  - 7.2.1.1 FISH PROBE, BY PROBE TYPE 109
    - 7.2.1.1.1 CHROMOSOME FISH PROBE 109
    - 7.2.1.1.2 SPLIT FISH PROBES 109
    - 7.2.1.1.3 TRANSLOCATION FISH PROBES 109
    - 7.2.1.1.4 SUBTELOMERE FISH PROBES 109
    - 7.2.1.1.5 PRENATAL FISH PROBES 109
    - 7.2.1.1.6 OTHERS PROBES 110
  - 7.2.1.2 FISH PROBE, BY TECHNOLOGY 110
    - 7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 110
    - 7.2.1.2.2 C-ISH 110
    - 7.2.1.2.3 D-ISH 110
    - 7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 110
    - 7.2.1.2.5 OTHERS 110
  - 7.2.1.3 FISH PROBE, BY TYPE 111
    - 7.2.1.3.1 RNA 111
    - 7.2.1.3.1.1 MRNA 111
    - 7.2.1.3.1.2 MIRNA 111
    - 7.2.1.3.1.3 OTHERS 112
    - 7.2.1.3.2 DNA 112
- 7.2.2 ACCESSORY KITS & REAGENTS 112
  - 7.2.2.1 KITS 112
  - 7.2.2.2 BUFFER 112
  - 7.2.2.3 DYES 112
  - 7.2.2.4 OTHERS 113
7.3 INSTRUMENT 113
- 7.3.1 STANDALONE 114
- 7.3.2 PORTABLE 114
- 7.3.3 HANDHELD 114
7.4 SOFTWARE 114

8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 115

8.1 OVERVIEW 116
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 119
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 120
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 121
8.5 OTHERS 122

9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 123

9.1 OVERVIEW 124
9.2 CANCER RESEARCH 127
- 9.2.1 CANCER RESEARCH, BY CANCER TYPE 128
  - 9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 128
    - 9.2.1.1.1 BREAST CANCER 128
    - 9.2.1.1.2 LUNG CANCER 128
    - 9.2.1.1.3 MELANOMA 129
    - 9.2.1.1.4 PROSTRATE CANCER 129
    - 9.2.1.1.5 OVARIAN CANCER 129
    - 9.2.1.1.6 OTHERS 129
  - 9.2.1.2 HEMATOPOETIC MALIGNANCIES 129
    - 9.2.1.2.1 LEUKEMIA 129
    - 9.2.1.2.2 MULTIPLE MYELOMA 130
    - 9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 130
- 9.2.2 CANCER RESEARCH, BY PRODUCT 130
  - 9.2.2.1 CONSUMABLES 130
  - 9.2.2.2 INSTRUMENTS 130
  - 9.2.2.3 SOFTWARE 130
9.3 GENETIC RESEARCH 131
- 9.3.1 CYTOGENETICS 132
- 9.3.2 CHROMOSOMAL ABNORMALITIES 132
- 9.3.3 OTHERS 132
9.4 INFECTIOUS DISEASE 132
- 9.4.1 CONSUMABLES 133
- 9.4.2 INSTRUMENTS 133
- 9.4.3 SOFTWARE 133
9.5 PERSONALIZED MEDICINE 133
9.6 OTHERS 134

10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 135

10.1 OVERVIEW 136
10.2 RESEARCH 139
- 10.2.1 INSTRUMENTS 139
- 10.2.2 CONSUMABLES 140
- 10.2.3 SOFTWARE 140
10.3 CLINICAL 140
- 10.3.1 CONSUMABLES 141
- 10.3.2 INSTRUMENT 141
- 10.3.3 SOFTWARE 141
10.4 COMPANION DIAGNOSTIC 141
- 10.4.1 CONSUMABLES 142
- 10.4.2 INSTRUMENT 142
- 10.4.3 SOFTWARE 142

11 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 143

11.1 OVERVIEW 144
11.2 DIAGNOSTIC LABORATORIES 147
11.3 HOSPITALS & CLINICS 147
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 148
11.5 ACADEMIC & RESEARCH INSTITUTES 149
11.6 CONTRACT RESEARCH ORGANIZATIONS 149
11.7 OTHERS 150

12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 151

12.1 OVERVIEW 152
12.2 RETAIL SALES 155
12.3 ONLINE SALES 155
12.4 DIRECT TENDER 156
12.5 OTHERS 157

13 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 158

13.1 NORTH AMERICA 159
- 13.1.1 U.S. 172
- 13.1.2 CANADA 180
- 13.1.3 MEXICO 188

14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 196

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 196

15 SWOT ANALYSIS 197

16 COMPANY PROFILE 198

16.1 MERCK KGAA 198
- 16.1.1 COMPANY SNAPSHOT 198
- 16.1.2 REVENUE ANALYSIS 198
- 16.1.3 COMPANY SHARE ANALYSIS 199
- 16.1.4 PRODUCT PORTFOLIO 199
- 16.1.5 RECENT DEVELOPMENT 199
16.2 ABBOTT 200
- 16.2.1 COMPANY SNAPSHOT 200
- 16.2.2 REVENUE ANALYSIS 200
- 16.2.3 COMPANY SHARE ANALYSIS 201
- 16.2.4 PRODUCT PORTFOLIO 201
- 16.2.5 RECENT DEVELOPMENT 202
16.3 AGILENT TECHNOLOGIES, INC. 203
- 16.3.1 COMPANY SNAPSHOT 203
- 16.3.2 REVENUE ANALYSIS 203
- 16.3.3 COMPANY SHARE ANALYSIS 204
- 16.3.4 PRODUCT PORTFOLIO 204
- 16.3.5 RECENT DEVELOPMENT 204
16.4 F. HOFFMANN-LA ROCHE LTD. 205
- 16.4.1 COMPANY SNAPSHOT 205
- 16.4.2 REVENUE ANALYSIS 205
- 16.4.3 COMPANY SHARE ANALYSIS 206
- 16.4.4 PRODUCT PORTFOLIO 206
- 16.4.5 RECENT DEVELOPMENT 206
16.5 THERMO FISCHER SCIENTIFIC INC. 207
- 16.5.1 COMPANY SNAPSHOT 207
- 16.5.2 REVENUE ANALYSIS 207
- 16.5.3 COMPANY SHARE ANALYSIS 208
- 16.5.4 PRODUCT PORTFOLIO 208
- 16.5.5 RECENT DEVELOPMENT 209
16.6 ABCAM PLC. 210
- 16.6.1 COMPANY SNAPSHOT 210
- 16.6.2 REVENUE ANALYSIS 210
- 16.6.3 COMPANY SHARE ANALYSIS 211
- 16.6.4 PRODUCT PORTFOLIO 211
- 16.6.5 RECENT DEVELOPMENTS 211
16.7 ABNOVA CORPORATION 213
- 16.7.1 COMPANY SNAPSHOT 213
- 16.7.2 PRODUCT PORTFOLIO 213
- 16.7.3 RECENT DEVELOPMENT 213
16.8 BIO SB 214
- 16.8.1 COMPANY SNAPSHOT 214
- 16.8.2 PRODUCT PORTFOLIO 214
- 16.8.3 RECENT DEVELOPMENT 214
16.9 BIOCARE MEDICAL, LLC 215
- 16.9.1 COMPANY SNAPSHOT 215
- 16.9.2 PRODUCT PORTFOLIO 215
- 16.9.3 RECENT DEVELOPMENT 216
16.10 BIOCAT GMBH 217
- 16.10.1 COMPANY SNAPSHOT 217
- 16.10.2 PRODUCT PORTFOLIO 217
- 16.10.3 RECENT DEVELOPMENT 218
16.11 BIODOT 219
- 16.11.1 COMPANY SNAPSHOT 219
- 16.11.2 PRODUCT PORTFOLIO 219
- 16.11.3 RECENT DEVELOPMENT 219
16.12 BIOGENEX 220
- 16.12.1 COMPANY SNAPSHOT 220
- 16.12.2 PRODUCT PORTFOLIO 220
- 16.12.3 RECENT DEVELOPMENT 220
16.13 BIO-TECHNE 221
- 16.13.1 COMPANY SNAPSHOT 221
- 16.13.2 REVENUE ANALYSIS 221
- 16.13.3 COMPANY SHARE ANALYSIS 222
- 16.13.4 PRODUCT PORTFOLIO 222
- 16.13.5 RECENT DEVELOPMENT 222
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH 223
- 16.14.1 COMPANY SNAPSHOT 223
- 16.14.2 PRODUCT PORTFOLIO 223
- 16.14.3 RECENT DEVELOPMENT 224
16.15 EXCILONE 225
- 16.15.1 COMPANY SNAPSHOT 225
- 16.15.2 PRODUCT PORTFOLIO 225
- 16.15.3 RECENT DEVELOPMENT 225
16.16 GENEMED BIOTECHNOLOGIES, INC. 226
- 16.16.1 COMPANY SNAPSHOT 226
- 16.16.2 PRODUCT PORTFOLIO 226
- 16.16.3 RECENT DEVELOPMENT 226
16.17 KANEKA EUROGENTEC S.A. 227
- 16.17.1 COMPANY SNAPSHOT 227
- 16.17.2 PRODUCT PORTFOLIO 227
- 16.17.3 RECENT DEVELOPMENT 227
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH 228
- 16.18.1 COMPANY SNAPSHOT 228
- 16.18.2 PRODUCT PORTFOLIO 228
- 16.18.3 RECENT DEVELOPMENT 228
16.19 METASYSTEMS 229
- 16.19.1 COMPANY SNAPSHOT 229
- 16.19.2 PRODUCT PORTFOLIO 229
- 16.19.3 RECENT DEVELOPMENT 229
16.20 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION) 230
- 16.20.1 COMPANY SNAPSHOT 230
- 16.20.2 REVENUE ANALYSIS 230
- 16.20.3 PRODUCT PORTFOLIO 231
- 16.20.4 RECENT DEVELOPMENT 231
16.21 ZYTOMED SYSTEMS GMBH 232
- 16.21.1 COMPANY SNAPSHOT 232
- 16.21.2 PRODUCT PORTFOLIO 232
- 16.21.3 RECENT DEVELOPMENT 232

17 QUESTIONNAIRE 233

18 RELATED REPORTS 237

LIST OF TABLES

TABLE 1 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 61
TABLE 2 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 3 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 62
TABLE 4 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 63
TABLE 5 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 64
TABLE 6 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
TABLE 7 NORTH AMERICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
TABLE 8 NORTH AMERICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66
TABLE 9 NORTH AMERICA INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 10 NORTH AMERICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67
TABLE 11 NORTH AMERICA SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 72
TABLE 13 NORTH AMERICA RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 14 NORTH AMERICA DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 15 NORTH AMERICA PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 16 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 17 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 80
TABLE 18 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 19 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 82
TABLE 20 NORTH AMERICA NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 82
TABLE 21 NORTH AMERICA HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 83
TABLE 22 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 84
TABLE 23 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 24 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 85
TABLE 25 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 26 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 87
TABLE 27 NORTH AMERICA PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 28 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 29 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 92
TABLE 30 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 31 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 93
TABLE 32 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 33 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 95
TABLE 34 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 35 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 96
TABLE 36 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 100
TABLE 37 NORTH AMERICA DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 38 NORTH AMERICA HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 39 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 40 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 41 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 42 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 43 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108
TABLE 44 NORTH AMERICA RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 45 NORTH AMERICA ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 46 NORTH AMERICA DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 47 NORTH AMERICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 48 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 117
TABLE 49 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117
TABLE 50 NORTH AMERICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117
TABLE 51 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 118
TABLE 52 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 118
TABLE 53 NORTH AMERICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
TABLE 54 NORTH AMERICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 119
TABLE 55 NORTH AMERICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 119
TABLE 56 NORTH AMERICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120
TABLE 57 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 120
TABLE 58 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 121
TABLE 59 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 121
TABLE 60 NORTH AMERICA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 122
TABLE 61 NORTH AMERICA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 122
TABLE 62 NORTH AMERICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 123
TABLE 63 NORTH AMERICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 123
TABLE 64 NORTH AMERICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 123
TABLE 65 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 124
TABLE 66 NORTH AMERICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 124
TABLE 67 NORTH AMERICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 124
TABLE 68 NORTH AMERICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 125
TABLE 69 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 70 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 125
TABLE 71 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 72 U.S. CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 73 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 127
TABLE 74 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 127
TABLE 75 U.S. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 76 U.S. RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 77 U.S. ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 78 U.S. INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 79 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 129
TABLE 80 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 81 U.S. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 130
TABLE 82 U.S. NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 130
TABLE 83 U.S. HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 130
TABLE 84 U.S. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 131
TABLE 85 U.S. GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 86 U.S. INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 87 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 132
TABLE 88 U.S. RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 132
TABLE 89 U.S. CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 132
TABLE 90 U.S. COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 133
TABLE 91 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 133
TABLE 92 U.S. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 133
TABLE 93 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 94 CANADA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 95 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 135
TABLE 96 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 135
TABLE 97 CANADA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 136
TABLE 98 CANADA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 99 CANADA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 100 CANADA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 137
TABLE 101 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 137
TABLE 102 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 103 CANADA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 138
TABLE 104 CANADA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 138
TABLE 105 CANADA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 138
TABLE 106 CANADA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 139
TABLE 107 CANADA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 139
TABLE 108 CANADA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 139
TABLE 109 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 140
TABLE 110 CANADA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 140
TABLE 111 CANADA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 140
TABLE 112 CANADA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 141
TABLE 113 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 141
TABLE 114 CANADA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 141
TABLE 115 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
TABLE 116 MEXICO CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
TABLE 117 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 143
TABLE 118 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 143
TABLE 119 MEXICO FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 144
TABLE 120 MEXICO RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 121 MEXICO ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 122 MEXICO INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 123 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 145
TABLE 124 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 145
TABLE 125 MEXICO CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 146
TABLE 126 MEXICO NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
TABLE 127 MEXICO HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
TABLE 128 MEXICO CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 147
TABLE 129 MEXICO GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 147
TABLE 130 MEXICO INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 147
TABLE 131 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 148
TABLE 132 MEXICO RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 148
TABLE 133 MEXICO CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 148
TABLE 134 MEXICO COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 149
TABLE 135 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 149
TABLE 136 MEXICO FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 149

LIST OF FIGURES

FIGURE 1 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION 26
FIGURE 2 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION 29
FIGURE 3 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS 30
FIGURE 4 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 31
FIGURE 5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS 31
FIGURE 6 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS 32
FIGURE 7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID 34
FIGURE 8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID 36
FIGURE 9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS 38
FIGURE 10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION 42
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030 43
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030 43
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET 51
FIGURE 14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022 58
FIGURE 15 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 59
FIGURE 16 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 59
FIGURE 17 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE 60
FIGURE 18 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022 69
FIGURE 19 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 70
FIGURE 20 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030) 70
FIGURE 21 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE 71
FIGURE 22 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022 77
FIGURE 23 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 78
FIGURE 24 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030) 78
FIGURE 25 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE 79
FIGURE 26 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022 89
FIGURE 27 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION) 90
FIGURE 28 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030) 90
FIGURE 29 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE 91
FIGURE 30 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022 97
FIGURE 31 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION) 98
FIGURE 32 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030) 98
FIGURE 33 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE 99
FIGURE 34 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022 105
FIGURE 35 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 106
FIGURE 36 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 106
FIGURE 37 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 107
FIGURE 38 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022) 113
FIGURE 39 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022) 114
FIGURE 40 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030) 114
FIGURE 41 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030) 115
FIGURE 42 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030) 115
FIGURE 43 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY SHARE 2022 (%) 149